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Abstract
Degeneration of synaptic and axonal compartments of neurons is an early event contributing to the pathogenesis of many
neurodegenerative diseases, but the underlying molecular mechanisms remain unclear. Here, we demonstrate the
effectiveness of a novel ‘‘top-down’’ approach for identifying proteins and functional pathways regulating neurodegen-
eration in distal compartments of neurons. A series of comparative quantitative proteomic screens on synapse-enriched
fractions isolated from the mouse brain following injury identified dynamic perturbations occurring within the proteome
during both initiation and onset phases of degeneration. In silico analyses highlighted significant clustering of proteins
contributing to functional pathways regulating synaptic transmission and neurite development. Molecular markers of
degeneration were conserved in injury and disease, with comparable responses observed in synapse-enriched fractions
isolated from mouse models of Huntington’s disease (HD) and spinocerebellar ataxia type 5. An initial screen targeting
thirteen degeneration-associated proteins using mutant Drosophila lines revealed six potential regulators of synaptic and
axonal degeneration in vivo. Mutations in CALB2, ROCK2, DNAJC5/CSP, and HIBCH partially delayed injury-induced
neurodegeneration. Conversely, mutations in DNAJC6 and ALDHA1 led to spontaneous degeneration of distal axons and
synapses. A more detailed genetic analysis of DNAJC5/CSP mutants confirmed that loss of DNAJC5/CSP was
neuroprotective, robustly delaying degeneration in axonal and synaptic compartments. Our study has identified conserved
molecular responses occurring within synapse-enriched fractions of the mouse brain during the early stages of
neurodegeneration, focused on functional networks modulating synaptic transmission and incorporating molecular
chaperones, cytoskeletal modifiers, and calcium-binding proteins. We propose that the proteins and functional pathways
identified in the current study represent attractive targets for developing therapeutics aimed at modulating synaptic and
axonal stability and neurodegeneration in vivo.
Citation: Wishart TM, Rooney TM, Lamont DJ, Wright AK, Morton AJ, et al. (2012) Combining Comparative Proteomics and Molecular Genetics Uncovers
Regulators of Synaptic and Axonal Stability and Degeneration In Vivo. PLoS Genet 8(8): e1002936. doi:10.1371/journal.pgen.1002936
Editor: Andrew D. Chisholm, University of California San Diego, United States of America
Received December 20, 2011; Accepted July 18, 2012; Published August 30, 2012
Copyright:  2012 Wishart et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from the Wellcome Trust (THG, MRF), Department of Defense BCRP (TMR), and NIH RO1 NS059991 (MRF). TMW is
currently supported by Roslin Institute Strategic Grant funding from the BBSRC. MRF is an Early Career Scientist of the Howard Hughes Medical Institute. The
funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: T.Gillingwater@ed.ac.uk
Introduction
Synaptic and axonal compartments of neurons are exceptionally
vulnerable to a wide array of neurodegenerative stimuli, ranging
from physical trauma through to genetic disease [1]. As a result,
the important role that synapses and axons play in the initiation
and progression of a wide range of neurodegenerative conditions is
becoming increasingly well documented. For example, published
studies have highlighted an important role for synaptic malfunc-
tion and degeneration in pre-clinical and early-symptomatic stages
of Alzheimer’s disease [2], Parkinson’s disease [3], Huntington’s
disease (HD) [4], spinocerebellar ataxia [5], prion diseases [6],
lysosomal storage disorders [7] and motor neuron diseases [8,9].
In many such conditions, synaptic and axonal pathology is
instigated in advance of pathological changes in other regions of
the neuron (e.g. the cell soma). Thus, neuroprotective strategies
directly targeting synapses and axons are likely to provide
important options for treating neurodegenerative disorders in
human patients [1,10,11].
Despite an increasing awareness of the scientific and clinical
importance of synaptic and axonal degeneration, little is known
about why distal compartments of neurons are particularly
vulnerable. Furthermore, our understanding of molecular and
genetic mechanisms regulating neurodegeneration remains in its
infancy. Of the many proteins present in synapses and distal axons,
only a few have been shown to be capable of directly modulating
neurodegeneration. One of the most extensively characterised, the
chimeric Wallerian degeneration slow (WldS) protein [12–14], is
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encoded by a novel chimeric gene formed by a spontaneous
mutation event in laboratory mice. It is not, therefore, endoge-
nously expressed in other species, including humans. Examples of
endogenous proteins capable of modulating synapse and distal
axon degeneration in vivo are relatively rare, including cysteine
string protein alpha (also known as DNAJC5) [15] and some
synucleins [16,17] (for review see [11]). There is, therefore, a need
to identify other proteins and pathways capable of modulating
synaptic and axonal stability and degeneration in vivo. However,
this is likely to require the development of integrated experimental
approaches capable of identifying and characterizing molecular
responses to degeneration in distal compartments of neurons.
Here, we report on the development of a novel ‘top-down’
approach for identifying proteins and functional pathways
regulating neurodegeneration in distal compartments of neurons
in vivo. We combined sequential comparative proteomic screens on
synapse-enriched fractions isolated from the mouse brain under-
going injury-induced degeneration with molecular genetic dissec-
tion of mechanisms underlying degeneration in Drosophila. We
show that synaptic and axonal degeneration is associated with
dynamic perturbations to the proteome, impacting on molecular
pathways involved with synaptic transmission and neurite devel-
opment. Experiments on two mouse models of neurodegenerative
disease (Huntington’s disease and spinocerebellar ataxia type 5)
showed that molecular pathways underlying distal neuron
degeneration were conserved from injury to disease. Genetic
manipulation of 13 synaptic proteins using mutant Drosophila lines
led to the identification of 6 potential regulators of axonal and
synaptic degeneration in vivo: ALDHA1 (Aldehyde dehydroge-
nase), CALB2 (calbindin2), DNAJC5/CSP (DnaJ (Hsp40) homo-
log, subfamily C, member 5), DNAJC6 (DnaJ (Hsp40) homolog,
subfamily B, member 6), HIBCH (3-hydroxyisobutyryl-CoA
hydrolase) and ROCK2 (Rho-associated, coiled-coil containing
protein kinase 2). A more robust genetic analysis of DNAJC5/CSP
confirmed that loss of this synaptic protein was neuroprotective,
robustly delaying degeneration in axonal and synaptic compart-
ments of neurons in vivo. We conclude that conserved molecular
responses are instigated locally within distal compartments of
neurons during the early stages of neurodegeneration. Such
responses are focused around networks of proteins modulating
synaptic transmission, incorporating molecular chaperones, cyto-
skeletal modifiers, and calcium binding proteins.
Results
Proteomic identification of molecular responses to
degeneration in synapse-enriched fractions of the mouse
brain
To uncover molecular pathways activated in synapses and
axons during the early stages of neurodegeneration we initially
wanted to obtain a global overview of protein expression changes
occurring locally within distal neuronal compartments undergoing
degeneration in response to a defined stimulus. We therefore
performed a series of comparative, unbiased proteomic screens on
synapse-enriched fractions biochemically isolated from the mouse
brain (see Methods and Figure 1A) [18]. The relative absence of
nuclear proteins (BRCA2) and glial cell proteins (MBP), alongside
robust levels of synaptic proteins synaptophysin and synapsin 1
(Figure 1A), confirmed the enrichment of synaptic material in
these preparations. However, it should be noted that low-level
contamination originating from other cell types and/or non-
synaptic fractions is likely to be present in these preparations.
Synaptic and distal axon degeneration was induced using an in
vivo cortical lesion model that injures cell bodies and proximal
axons giving rise to corticostriatal projections. In this model
unilateral ablation of one cortical hemisphere down to the level of
the corpus callosum reliably triggers axonal and synaptic
degeneration in the underlying ipsilateral striatum [14,19].
Morphological evidence for axonal and synaptic degeneration is
not observed until 48 hours following injury in wild-type mice
(C57Bl/6) [14,19], revealing the presence of a ,24–48 hour lag
period preceding the physical onset of degeneration. We therefore
generated synapse-enriched fractions preparations from the
striatum of wild-type mice at 3 time points (N = 6 mice per time
point): prior to injury (0 hrs), providing a base-line for protein
detection and expression; 24 hours following injury (24 hrs) to
identify immediate early responses triggered during the initiation
of degeneration; and 48 hours following injury (48 hrs), correlat-
ing with the onset of synaptic breakdown. In order to increase
stringency in reporting, a minimum cut-off threshold of 20%
change versus uninjured controls was used to indicate a protein
with modified expression levels. iTRAQ (Isobaric Tag for Relative
and Absolute Quantitation) proteomic analyses identified a total of
178 putative proteins (from a pool of 56,957 peptide sequences)
with expression levels modified by more than 20% at either 24 h
or 48 hr after injury compared to uninjured (0 hrs) controls. Of
these, 112 putative proteins showed expression changes of greater
than 20% maintained at 48 hrs following injury (Table S1).
Bioinformatics analysis of the 178 putative proteins using IPA
software revealed that .87% of the proteins were cytoplasmic or
membrane bound, consistent with them being synaptic proteins,
rather than arising as a result of contamination from nuclear
compartments.
Modifications to the proteome of synapse-enriched fractions
revealed in our initial analyses are unlikely to solely represent
responses directly associated with degeneration, as the cortical
lesion injury used generated systemic responses in corticostriatal
networks that could conceivably effect the molecular composition
of the tissue (e.g. in response to modified patterns of activity). In
Author Summary
In diseases affecting the nervous system, such as
Alzheimer’s disease and motor neuron disease, the
breakdown of synaptic connections between neurons is
a critical early event, contributing to disease onset and
progression. However, we still know very little about the
molecular machinery present in synaptic and axonal
compartments of neurons that regulate their stability
and cause breakdown during neurodegeneration. In this
study we examined the protein composition of healthy
and degenerating synapse-enriched fractions isolated from
the brains of mice in order to identify early molecular
changes occurring during neurodegeneration. We identi-
fied a range of proteins and cellular pathways that were
modulated in synapse-enriched fractions during the early
phases of degeneration, many of which were already
known to regulate synaptic function. Similar molecular
alterations were found in synapse-enriched fractions
prepared from mouse models of Huntington’s disease
(HD) and spinocerebellar ataxia type 5. Data from these
proteomic studies were then used to design experiments
in Drosophila, in which we found that at least six of the
individual proteins modified in degenerating synapses
from mice were capable of independently regulating
neuronal stability and degeneration in vivo. Designing
novel therapeutics to target these proteins and pathways
may help to delay or prevent neurodegeneration across a
range of diseases.
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order to improve our dataset, leaving only molecular responses
directly associated with active processes of degeneration, we refined
our analysis by undertaking a subsequent comparison with
proteomic data obtained from synapse-enriched fractions in mice
genetically protected from neurodegeneration by the Wlds gene. We
have previously demonstrated that both axonal and synaptic
degeneration in the striatum are absent for at least 6 days after a
cortical lesion in Wlds mice [14,19]. We therefore reasoned that any
alterations to the proteome observed in Wlds mice at either 24 hrs or
48 hrs after injury were more likely to represent systemic responses
to the lesion injury itself rather than changes directly related to the
process of synaptic and axonal degeneration. iTRAQ proteomic
analyses were therefore performed on tissue from Wlds mice using
the same protocol adopted for our initial experiments on wild-type
animals. Through subtracting candidates identified in synapse-
enriched fractions from both wild-type and Wlds mice following
injury (Table S2; validated using western blotting at 72 hrs after
injury, Figure 1B), we refined our dataset to include only those
putative proteins with modified expression in synapse-enriched
fractions undergoing degeneration (Figure 1C–1D). This approach
removed a total of 19 candidates from the dataset, resulting in a
refined profile comprised of 93 putative proteins.
Given that we planned to use data generated by our proteomics
analysis to directly guide subsequent molecular genetic experiments
in Drosophila (see below), we wanted to exclude any of the 93 putative
proteins identified for which we could not be certain of their identity
based on the peptide sequences reported from the proteomics
analysis. We therefore excluded all putative proteins identified only
by 1 unique peptide that we could not subsequently validate by
western blotting. Examples of validation western blots for one up-
regulated (ABLIM1) and one down-regulated (UBR4) protein are
shown in Figure 2A. This generated a final refined list of 47 unique
proteins with robustly modified expression in synapse-enriched
fractions 48 hrs after injury (Table S3; Figure 2B). These 47
proteins were therefore considered to represent robust molecular
perturbations occurring in synapse-enriched fractions during the
initiation and onset phases of neurodegeneration in vivo.
A complex temporal profile of protein expression
changes during neurodegeneration
Expression mapping of all 47 proteins identified as having
modified expression levels in degenerating synapse-enriched
fractions allowed them to be grouped according to the temporal
dynamics of their responses, as well as magnitude of expression
change (Figure 2B). Given that synaptic degeneration was absent
in the striatum 24 hrs after cortical lesion, but was widespread at
48 hrs after lesion [14,19], we reasoned that individual proteins
responding within 24 hrs of lesion were more likely to represent
immediate-early responders and initiators of the degeneration
process. By contrast, we reasoned that individual proteins whose
expression levels were found to be altered only at 48 hrs after the
lesion were more likely to represent effector pathways involved
with the onset of degeneration.
Diverse temporal patterns of expression changes were observed
across the 47 proteins examined, suggesting that our analyses had
detected proteins contributing both to early initiating phases and
onset phases of degeneration (Figure 3). Of the 47 synaptic proteins
identified 24 responded within 24 hrs of injury. Of these, 14
remained stable at 48 hrs whereas 10 showed additional incremen-
tal changes by 48 hrs. The other 23 proteins were unchanged at
24 hrs, responding only at 48 hrs after injury (Figure 3).
In silico analysis revealed significant functional clustering
of proteins
Next, we wanted to establish whether the profile of individual
protein alterations identified in degenerating synapse-enriched
fractions represented perturbations of specific functional pathways.
We performed an in silico systems level analysis on the proteomics
Figure 1. Proteomic identification and refinement of molecular pathways underlying degeneration in synapse-enriched brain
fractions. A. Representative bands from fluorescent western blots demonstrating enrichment of two distinct synaptic proteins (synaptophysin and
synapsin-1) and relative purity of the synapse-enriched fractions, comparatively free from nuclear contamination (BRCA2) and glial cell contamination
(MBP) relative to non-synaptic fractions. Actin is shown as a loading control. B. Representative bands from fluorescent western blots showing
examples of protein expression changes (VAT1 and DOCK7) present in striatal synapse-enriched fractions from both wild-type and WldS mice before
(0D) and 3 days after (3D) cortical lesion. Both proteins showed similar alterations in expression in degenerating tissue across wild-type and WldS mice
suggesting that they are more likely to represent systemic responses to injury rather than direct mediators of the degenerative process (as synaptic
degeneration is yet to be initiated in WldS mice 3 days after lesion [14]). Tubulin is shown as a loading control. C/D. Pie charts representing all proteins
found to have altered expression .20% following cortical lesion. The blue section of each chart represents those proteins altered only in wild-type
mice. The red sections show those proteins found to be altered in both wild-type and WldS mice, which were subsequently subtracted from the
proteomic profile as they were not considered to represent expression changes underlying degeneration.
doi:10.1371/journal.pgen.1002936.g001
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data using Ingenuity Pathway Analysis (IPA) software. This
analysis identifies statistically significant functional clustering of
proteins, based on known protein interactions and biological
functions reported in the published literature [18]. Functional
networks identified by the IPA software are statistically ranked
according to a score calculated via a right-tailed Fischer’s exact
test, taking into account the number of original input proteins and
the size of the network generated as a result. Only networks
comprised of 3 or more identified proteins and reported with a P
value of ,0.05 were considered as being significant. These
experiments revealed that the 47 identified proteins were
functionally clustered into a relatively small group of networks
(Table S4), focused principally around pathways regulating
synaptic function (including synaptic transmission, exocytosis,
transport of vesicles and formation of vesicles) and neurite
development (including guidance of axons, formation of filaments,
development of neurites and biogenesis of the cytoskeleton).
The in silico analysis also highlighted many proteins previously
implicated in molecular pathways underlying neurological condi-
tions (Table S4). Interestingly, these included neurodegenerative
conditions where synapses and axons are known to be primary
pathological targets (e.g. Alzheimer’s disease, Parkinson’s disease
and HD; see introduction).
Molecular pathways underlying synapse pathology are
conserved from injury to disease
Next, we wanted to establish whether molecular pathways
modified as a result of injury-induced degeneration were similarly
Figure 2. Temporal expression profiling identifies molecular changes occurring in synapse-enriched fractions from the striatum
undergoing degeneration. A. Representative bands from fluorescent western blots for one up-regulated protein (Ablim1) and one down-
regulated protein (Ubr4) in degenerating synapse-enriched fractions, validating expression changes observed in proteomic experiments. Tubulin is
shown as a loading control. B. Graphical representation of protein expression changes for all 47 proteins modified in degenerating synapse-enriched
fractions (see Table 1), illustrating global trends in the magnitude and scope of alterations identified.
doi:10.1371/journal.pgen.1002936.g002
Figure 3. Temporal expression profiling for individual proteins identified in synapse-enriched fractions undergoing degeneration.
Temporal profiles of protein expression changes in degenerating synapse-enriched fractions were grouped into 3 distinct categories: proteins with
expression changes .20% by 24 hours, with further progressive alterations by 48 hours (A); proteins up or down regulated .20% by 24 hours
following injury but with no subsequent increase/decrease (B); and proteins not changed at 24 hours but up or down regulated .20% at 48 hours
following injury (C). Proteins responding within 24 hrs of lesion were considered to represent immediate-early responders and initiators of the
degeneration process, whereas proteins whose expression levels were found to be altered only at 48 hrs after the lesion were considered to
represent effector pathways involved with the onset of degeneration.
doi:10.1371/journal.pgen.1002936.g003
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modified in synapse-enriched fractions undergoing pathological
alterations in neurodegenerative diseases resulting from genetic
mutations. We therefore selected 11 proteins from our injury
proteomics data where reliable antibodies were available for use in
quantitative fluorescent western blotting experiments (ABLIM1,
SPBTN, CCT7/TCP1, CFL1, CNP, DNAJC5/CSP, INPP4A,
NFASC, ROCK2, SIRT2 and UBR4). These included candidates
from the top five cellular process categories identified in our
functional clustering analysis (see Table S4). We quantified
expression levels in synapse-enriched fractions isolated from two
distinct mouse models of neurodegenerative disease at early-
symptomatic time-points: a genetic disease model with synaptic
degeneration (the R6/2 mouse model of HD) and a model of
spinocerebellar ataxia type 5 with synaptic dysfunction/dysregu-
lation (bIII-spectrin knockout mouse).
The pathophysiology of HD involves aggregation of mutated
huntingtin (Htt) protein, transcriptional dysregulation, altered
energy metabolism, excitotoxicity, impaired axonal transport and
synaptic pathology [20]. The R6/2 mouse model of HD exhibits a
progressive and fatal neurological phenotype, with synaptic
alterations notable in the striatum [4]. Protein expression levels
were analysed in synapse-enriched fractions generated from the
striatum of R6/2 mice carrying a CAG repeat of 259–266 at 9–10
weeks of age (representing early-symptomatic stages of the disease).
Of the 11 proteins examined, 8 showed significant changes in
expression levels in fractions prepared from R6/2 mice (Figure 4A
and 4B).
The bIII-spectrin knockout mouse models many of the human
aspects of spinocerebellar ataxia type 5, including; synaptic
dysfunction, postural abnormalities, progressive loss of motor
coordination, and cerebellar degeneration [5]. Protein expression
levels were analysed in synapse-enriched fractions generated from
the cerebellum of bIII-spectrin knockout mice at 12 weeks of age
(representing early-symptomatic stages of the disease [5]). Of the
10 proteins examined (SPTBN is knocked out in these mice), 7
showed significant changes in expression levels in bIII-spectrin
knockout mice (Figure 4C and 4D).
Comparisons of protein expression data obtained from the
cortical lesion model, R6/2 model and bIII-spectrin knockout
revealed that 9 of the examined proteins showed expression
changes occurring in the same direction across all three models
(Figure 4E). Although the magnitude of identified expression
changes were not always identical between models (and often were
variable between individual mice), this likely represents the
differing extent and nature of synaptic pathology observed
between the three models at the time-points examined [4,5,14].
Identification of individual proteins capable of
independently regulating synapse and distal axon
degeneration in vivo
Although we had obtained a clear understanding of conserved
molecular alterations occurring in synapse-enriched fractions
undergoing neurodegeneration, it remained unclear whether or
Figure 4. Molecular pathways underlying degeneration in
synapse-enriched fractions are conserved across diverse
neurodegenerative conditions. A. Bar chart (mean6SEM) showing
quantitative fluorescent western blot data for protein expression levels
in synapse-enriched fractions from the striatum generated from the R6/
2 transgenic mouse model of HD compared to wild-type controls (N$3
mice per genotype). Bars to the left of the dotted line show levels of
control proteins (including Huntingtin [HTT]). Bars to the right of the
dotted line show levels of proteins previously identified following injury
(see Table 1). NS =not significant; *P,0.05; **P,0.01; Mann-Whitney
test. B. Representative bands from quantitative fluorescent western blot
experiments on synapse-enriched fractions from wild-type (WT) and R6/
2 mice. C. Bar chart (mean6SEM) showing quantitative fluorescent
western blot data for protein expression levels in synapse-enriched
fractions from the cerebellum generated from a mouse model of
spinocerebellar ataxia type 5 (bIII-spectrin KO mice) compared to wild-
type controls (N$3 mice per genotype). Bars to the left of the dotted
line show levels of control proteins (including bIII-spectrin [SPTBN]).
Bars to the right of the dotted line show levels of proteins previously
identified following injury (see Table 1). NS =not significant; *P,0.05;
**P,0.01; Mann-Whitney test. D. Representative bands from quantita-
tive fluorescent western blot experiments on synapse-enriched
fractions from wild-type (WT) and bIII-spectrin mice (KO). E. Comparison
of protein expression changes in synapse-enriched fractions from the
injury model (summarized from the proteomics data), R6/2 mice and
bIII-spectrin KO mice. Red boxes indicate mean expression decreased
.10%, green boxes indicate mean expression increased .10%, grey
boxes indicate changes ,10%. Up= significantly upregulated com-
pared to controls; Down= significantly downregulated compared to
controls; NS =not significantly changed compared to controls.
doi:10.1371/journal.pgen.1002936.g004
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not any of the proteins and pathways identified were capable of
actively modulating synaptic and axonal stability and degeneration
in vivo. We therefore used a molecular genetic approach in
Drosophila to screen individual proteins for a direct role in
neurodegeneration.
We examined the role of individual proteins in regulating
synaptic stability and degeneration using the Drosophila olfactory
system to screen a collection of existing mutants, or lines with
transposon insertions in a subset of these genes. Briefly, mutants
and insertion lines were crossed in to a background that allowed
visualization of a subset of olfactory receptor neurons (ORNs;
OR22a-Gal4/UAS-mCD8::GFP). Distal axons and their synaptic
fields in the antennal lobe were examined in uninjured controls as
well as 7 days after surgical ablation of antennae. Examining
uninjured controls allowed us to screen individual mutant lines
and test whether they modified basal synaptic and axonal stability
(e.g. do synapses and axons degenerate spontaneously in the
mutant line?). Spontaneous degeneration was identified by the
presence of fragmented axons and absence/decrease of GFP signal
in the glomeruli housing synaptic terminals of ORNs [21] and
scored using a spontaneous degeneration index, where a score of 0
represented no disruption of axons or synapses in the glomerulus
and 5 indicated complete spontaneous breakdown (see methods;
Figure 5). Surgical ablation of antennae triggered rapid axonal and
synaptic degeneration, which is complete within one day in wild-
type controls, and axonal debris is cleared within one week after
injury [21]. Screening individual mutant lines 7 days after surgical
ablation therefore allowed us to examine whether any of the
mutations resulted in a delay in the rate of injury-induced
degeneration, scored using a delayed degeneration index where a
score of 0 indicated no delay in degeneration and 5 indicated a
complete block (see methods; Figure 5).
From our original list of 47 synaptic proteins we obtained
Drosophila lines for 21 different genes that harbored either defined
mutations known to affect that gene, or P element insertions within
the locus identified by the Drosophila Genome Project (see
methods). Of the 34 mutant lines obtained, 14 produced viable
flies suitable for analyses of axonal and synaptic stability and
degeneration (covering a total of 13 individual proteins; Table 1).
Eight of the lines examined showed no overt phenotype in either
stability or degeneration assays (Table 1). However, 6 mutant lines
were found to independently modulate stability or degeneration of
distal axons and synapses in ORNs. Mutants of both ALDHA1
and DNAJC6/Auxillin caused spontaneous degeneration of distal
Figure 5. Overview of putative axo-synaptic degeneration
phenotypes observed in Drosophila neurodegeneration
screens. A. Representative confocal micrograph showing the mor-
phology of the intact Drosophila olfactory receptor neuron (ORN)
system, with axons and synaptic fields labeled with GFP in the UAS-
mCD8::GFP,OR22a-Gal4/+ background. Axons enter the antennal lobe
laterally and project medially across the lobe to reach their target
glomerulus, where synapses are located (see reference [21]). B.
Representative confocal micrographs showing three distinct phenotyp-
ic profiles observed in injured and un-injured ORN axons and synapses
7 days after unilateral (right hand side of image) antennal ablation. The
top panel shows intact healthy axons and synapses on the uninjured
side and complete axonal degeneration (indicated by absence of GFP
labeled profiles) on the injured side (example from an NFASC mutant).
The middle panel shows delayed axo-synaptic degeneration on the
injured side, as indicated by the retention of GFP-labelled axon profiles
7 days after injury (white arrow; example from a ROCK2 mutant). The
bottom panel shows spontaneous (i.e. not injury-induced) axo-synaptic
degeneration in the uninjured axons and synapses, indicated by
reduction and fragmentation of GFP labeled axons and synapses (white
arrows; example from a DNAJC6 mutant). C. Bar chart (mean6SEM)
showing index scores (see methods) for spontaneous degeneration (S;
grey bars) and delayed degeneration (D; black bars) in 7 mutant
Drosophila lines. OGDH is shown as an example of a mutant line with no
overt phenotype. DNAJC6 and ALDH1A1 mutants revealed evidence for
spontaneous degeneration in the absence of any injury stimulus.
DNAJC5, CALB2, ROCK2 and HIBCH mutants revealed evidence for
delayed degeneration following antennal ablation.
doi:10.1371/journal.pgen.1002936.g005
Regulators of Synaptic and Axonal Degeneration
PLOS Genetics | www.plosgenetics.org 6 August 2012 | Volume 8 | Issue 8 | e1002936
axons and synaptic terminals in uninjured ORNs (Figure 5). In
contrast, mutations affecting CALB2/Calretinin, DNAJC5/CSP,
HIBCH and ROCK2 caused a partial delay of injury-induced
degeneration of axons and synapses (Figure 5). In each of these lines,
intact distal axons or axonal fragments were observed 7 days after
experimental nerve lesion, a time-point at which axonal remnants
were never observed in wild-type flies (data not shown [21]).
To provide more robust genetic evidence for a role for one of
these proteins (DNAJC5/CSP) in axonal and synaptic degenera-
tion, we obtained two additional alleles: cspX1, a loss of function
allele which deletes the first exon of csp; and Df(3R)Exel6138, a
deletion which completely removes the csp locus. Both cspX1 and
Df(3R)Exel6138 failed to complement the delay in axonal
degeneration observed with our original allele (cspDG29203), thereby
mapping this phenotype to the csp locus (Figure 6). We further note
that the severity of the delay in axonal degeneration appeared to
be enhanced when cspDG29203 was placed over either of these null
alleles of csp, which argues that cspDG29203 is a weak loss of function
allele.
Thus, several individual proteins initially identified as a result of
having modified expression levels in synapse-enriched fractions
undergoing neurodegeneration appear capable of directly influ-
encing synaptic and axonal stability and degeneration in Drosophila.
In addition, our work rigorously defines the role of DNAJC5/CSP
as an in vivo regulator of synaptic and axonal degeneration.
Discussion
In this study we report on the effective use of a novel ‘top-down’
approach for identifying individual proteins and functional
pathways responsible for regulating neurodegeneration in synaptic
and axonal compartments of neurons. By undertaking a series of
comparative quantitative proteomic screens on degenerating
synapse-enriched fractions isolated from the mouse brain we
identified 47 proteins with robustly modified expression levels
during the early stages of neurodegeneration. We showed that
molecular responses to degeneration occurring in synapse-
enriched fractions following injury were recapitulated in synapse-
enriched fractions undergoing pathological changes as a result of
disease-causing genetic mutations. We also used our proteomic
data to design molecular genetic screens in Drosophila that revealed
roles for 6 proteins in regulating synaptic and axonal degeneration
Figure 6. Detailed genetic analysis confirms DNAJC5/CSP as a robust regulator of axo-synaptic degeneration in vivo. Representative
confocal micrographs showing axon degeneration profiles in wild-type (WT) flies and additional DNAJC5/CSP lines: cspX1, a loss of function allele
which deletes the first exon of csp; and Df(3R)Exel6138, a deletion which completely removes the csp locus. Examples are shown of uninjured axons
(left panels), unilaterally injured axons (middle panels) and bilaterally injured axons (right panels). Both cspX1 and Df(3R)Exel6138 failed to complement
the delay in axonal degeneration observed with our original allele (cspDG29203), thereby mapping this phenotype to the csp locus. Note how the
severity of the delay in axonal degeneration was enhanced when cspDG29203 was placed over either of these null alleles of csp, suggesting that
cspDG29203 is a weak loss of function allele.
doi:10.1371/journal.pgen.1002936.g006
Table 1. List of viable Drosophila lines tested in the current
study.
Protein Bloomington ID Observation
ALDHA1 12900 Spontaneous Degeneration
Auxillin/DNAJC6 26277 Spontaneous Degeneration
CALB2/calretinin 18382 Delayed Degeneration
CFL1 7762 No Overt Phenotype
CSP/DNAJC5 20497 Delayed Degeneration
DLG1 12301 No Overt Phenotype
HIBCH 30075 Delayed Degeneration
HTT 24665 No Overt Phenotype
INPP4A 18046 No Overt Phenotype
NFASC 5595 No Overt Phenotype
OGDH 23173 No Overt Phenotype
ROCK2 6671 Delayed Degeneration
VPS29 13491, 20672 No Overt Phenotype
doi:10.1371/journal.pgen.1002936.t001
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in vivo. These findings further our understanding of mechanisms
regulating the active degeneration of synapses and axons,
providing a basis from which to develop novel neuroprotective
strategies for a range of neurodegenerative conditions.
An initial comparison of the 6 individual proteins found to
directly mediate synaptic and axonal stability and degeneration in
our Drosophila screen reveals a diverse range of biological functions.
For example, both DNAJC5/CSP and DNAJC6 belong to the
evolutionarily conserved DNAJ/HSP40 family of proteins that
regulate molecular chaperone activity by stimulating ATPase
activity [22], whereas CALB2/calretinin is an intracellular
calcium-binding protein [23] and ROCK2 is a Rho kinase
belonging to a family of serine/threonine kinases involved in
structural remodeling of the cytoskeleton [24]. Despite this
apparent heterogeneity, it should be noted that the in silico analysis
of data generated by our proteomics experiments highlighted
significant clustering of proteins within functional networks that
regulate synaptic transmission. This finding is further reinforced
by comparisons of the biological roles of the 6 proteins found to
independently regulate degeneration in our Drosophila screen, 5 of
which have been implicated in the control of synaptic function:
both CALB2/Calretinin and ALDHA1 modulate synaptic long-
term potentiation (LTP) [25,26], DNAJC6 has been implicated in
clatherin-mediated synaptic vesicle recycling [27,28], DNAJC5/
CSP plays a role in SNARE-complex assembly [29], and ROCK2
levels influence synaptic transmission and plasticity [30]. Taken
together with previous reports linking perturbations in synaptic
transmission with synaptic degeneration [11] (also see below), our
findings suggest that endogenous neuronal proteins and pathways
regulating synaptic function play an important role in modulating
neurodegenerative pathways.
It is worth noting, however, that at least one of the other
proteins found to influence degeneration in our Drosophila screen
(HIBCH; 3-hydroxyisobutyryl-CoA hydrolase) is unlikely to
impact directly on synaptic transmission pathways. HIBCH plays
an important role in valine catabolism, disruption of which is
sufficient to induce progressive infantile neurodegeneration in
humans [31]. Thus, multiple cellular and molecular pathways are
likely to converge on mechanisms regulating synaptic and axonal
degeneration. This finding is supported by our in silico analysis
revealing that several of the proteins identified in our screen also
contribute to pathways regulating neurite development. This
supports previous observations from Drosophila models linking
ubiquitin-mediated developmental processes with neurodegenera-
tive processes occurring in axonal compartments of neurons [32].
Thus, although proteins and pathways involved in synaptic
transmission are likely to contribute significantly to neurodegen-
eration, other distinct molecular pathways also appear to be
capable of influencing synaptic and axonal degeneration in vivo.
Only one of proteins we identified as a direct mediator of
degeneration, DNAJC5/CSP, belongs to the small group of
endogenous genes and proteins previously reported to directly
affect synaptic stability and degeneration in vivo. DNAJC5/CSP
has been implicated in synaptic degeneration contributing to the
pathogenesis of neurodegenerative diseases [11,33]. However, our
findings are partially inconsistent with previously published studies
examining the role of DNAJC5/CSP in animal models. For
example, Ferna´ndez-Chaco´n and colleagues reported that loss of
CSP expression in mice caused synaptic degeneration in the CNS,
leading them to conclude that increased levels of the protein may
be neuroprotective [15,34]. By contrast, we found that DNAJC5/
CSP levels are robustly and consistently increased in degenerating
synapse-enriched fractions following injury and in synapse-
enriched fractions from mouse models of neurodegenerative
disease. Moreover, a thorough genetic analysis in Drosophila using
well-defined mutants in DNAJC5/CSP revealed that loss of CSP is
neuroprotective, delaying degeneration in axonal and synaptic
compartments. Thus, whilst it is clear that DNAJC5/CSP needs to
be regarded as a critical regulator of-neuronal stability and
degeneration in vivo, precise details correlating expression levels
with its role in stabilizing distal axons and synapses during disease-
induced degeneration remain to be determined.
Given that only partial coverage of the entire synaptic proteome
is possible through the coupling of subcellular fractionation with
current proteomics technologies, alongside the stringent 20% cut
off threshold employed, the refinement methodologies applied in
the current study and the limited number of viable fly lines that we
screened, it is highly likely that additional genes and proteins
capable of regulating neurodegeneration remain to be discovered.
Our uncovering of molecular responses underlying neurodegen-
eration in distal compartments of neurons, alongside the
identification of 5 novel mediators of degeneration and new
experimental insights into the role of DNAJC5/CSP, suggests that
combining proteomic screens on synapse-enriched fractions with
axonal/synaptic degeneration assays in Drosophila provides a
powerful approach for elucidating mechanisms of neurodegener-
ation in vivo.
Materials and Methods
Ethics statement
All animal experiments were approved by a University of
Edinburgh internal ethics committee and were performed under
license by the UK Home Office (project license number 60/3891).
Mouse cortical lesion model
Two month old, female C57Bl/6 (wild-type) and Wlds mice
were obtained from Harlan Olac Laboratories (Bicester, UK) and
housed within the animal care facilities in Edinburgh. Care was
taken to ensure that the wild-type mice did not contain the alpha-
synuclein gene deletion that was present in a sub-strain of Harlan
Olac Bl6 mice [18]. All surgical procedures were performed under
license from the UK Home Office. General anaesthesia was
induced using a mixture of isopentane and oxygen, before securing
the head in a Kopf stereotaxic frame. Fur overlying the cranial
vault was shaved with scissors before making an incision through
the skin at the midline. Four holes were drilled on the left side of
skull; 1) in the midline at bregma, 2) in line with the first but at the
level of lambda, 3) further caudal on the lateral side just above the
temporalis muscle, 4) anterolateral in line with the first and third
holes. The skull was cut in lines connecting all holes except the
most caudal border, and then reflected. A suction pipette was used
to remove all visible cortex under a dissecting microscope, down to
the level of the corpus callosum, before replacing the skull-flap
[14,19]. The lesion site was filled with gel foam (Ethicon) before
replacing the skull-flap. Overlying skin was then sutured and the
mouse placed on a heated blanket until recovered fully from the
anaesthetic. Mice were maintained in standard animal house
conditions and were checked daily for any signs of distress or
discomfort as previously described [14,19].
Mouse disease models
R62 mice with a CAG repeat number of 259–266 from
breeding colonies at the University of Cambridge were sacrificed
at 9–10 weeks old. Mice were genotyped as previously described
[20]. Mice lacking bIII-spectrin and age-matched controls from
breeding colonies at the University of Edinburgh were raised and
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sacrificed at 12–15 weeks old. Mice were genotyped as previously
described [5].
Preparation of synapse-enriched fractions
Brains were rapidly removed following sacrifice and required
brain regions microdissected out (cerebellum from bIII-spectrin
mice, striatum from wild-type mice, Wlds mice subjected to a
cortical lesion and R6/2 mice). Synapse-enriched fractions were
prepared as previously described [18]. Briefly, brain regions were
homogenised in an ice-cold isotonic sucrose solution (0.32 M
sucrose, 1 mM EDTA, 5 mM Tris-HCl, pH 7.4). Homogenate
was centrifuged in a fixed-angle rotor at 900 g for 10 min and the
supernatant (S1) was collected. The pellet (P1) was resuspended in
sucrose solution and centrifuged again at 900 g for 10 min. The
resulting supernatant (S19) was combined with S1 and centrifuged
in a fixed angle rotor at 20,000 g for 15 min. The supernatant (S2)
was discarded and the pellet (P2) containing crude synapse-
enriched fractions was washed in a Krebs-like buffer (118.5 mM
NaCl, 4.7 mM KCl, 1.18 mM MgCl2, 0.1 mM K2HPO4, 20 mM
Hepes, 1.3 mM CaCl2, 10 mM glucose, pH 7.4) then centrifuged
at 14,000 g for 10 min.
Quantitative Western blots
Quantitative fluorescent western blotting was performed as
previously described [35]. Briefly, protein was extracted (N.3
mice per sample) in RIPA buffer with 10% protease inhibitor
cocktail (Sigma). 15–30 mg of protein per lane was separated by
SDS/Polyacrylamide gel electrophoresis on 4–20% pre-cast
NuPage 4–12% Bis Tris gradient gels (Invitrogen) and then
transferred to PVDF membrane overnight. The membranes were
then blocked using Odyssey blocking buffer (Li-COR) and
incubated with primary antibodies as per manufacturers instruc-
tions (ABLIM1, SPBTN, CCT7/TCP1, UBR4 - Santa Cruz;
Beta-actin, BIII-tubulin, CNP, CFL1, CSP, DOCK7, HTT,
INPP4A, NFASC, ROCK2, SIRT2, VAT1 - Abcam). Odyssey
secondary antibodies were added according to manufacturers
instructions (Goat anti rabbit IRDye 680 and Goat anti mouse
IRDye 800). Blots were imaged using an Odyssey Infrared
Imaging System (Li-COR Biosciences). Scan resolution of the
instrument ranges from 21–339 mm and in this study blots were
imaged at 169 mm.
iTRAQ proteomics
Protein was extracted from synapse-enriched fractions in
MEBC buffer (50 mM Tris, 100 mM NaCl, 5 mM NaEDTA,
5 mM NaEGTA, 40 mM glycerophosphate, 100 mM NAF,
100 mM Sodium orthovanadate, 0.25% NP40, 1 Roche ‘‘com-
plete’’ protease inhibitor tablet, pH 7.4) before acetone precipita-
tion and labeling for iTRAQ analysis as previously described [35].
Samples (N = 36 mice in total. N = 18 mice per genotype, N = 6
mice per time point) were precipitated with 220uC chilled acetone
(1:4, vol/vol) and stored at 220uC overnight. The precipitates
were spun at 4uC for 10 min then washed with an acetone:water
mixture (4:1, vol/vol) twice prior to air drying. The pellets were
then re-suspended in iTRAQ sample buffer (25 ml 500 mM
TEAB, 1 ml denaturant (2% SDS) and 2 ml of reducing agent
(TCEP)). The samples were allowed to incubate for 1 hour at
60uC prior to protein estimation in triplicate (361 ml) by
microBCA assay (Pierce).
Aliquots of each sample equivalent to 100 mg were made up to
28 ml using the iTRAQ sample buffer minus denaturant. To each
sample 1 ml of 84 mM IAA was added, the samples mixed and
spun prior to incubation at room temperature in the dark for
30 minutes. To each sample 10 ml of a 1 ml/ml solution of trypsin
(Sequencing grade, Roche) in water was added and the samples
incubated overnight on a shaking platform at 30uC. To each vial
of iTRAQ reagent (113, 114, 115, 116, 117, 118) 70 ml of ethanol
was added, mixed and spun prior to transfer to each sample vial
(WT0 hrs-114, WT24 hrs-116, WT48 hrs-118; Wlds0 hrs-113,
Wlds24 hrs-115, Wlds48 hrs-117). The pH was checked for each
sample to ensure pH was greater than 8.0 prior to incubation for
1 hour at room temperature. 100 ml of water was added to each
sample to quench the reaction prior to pooling of the six iTRAQ
labelled samples and subsequent drying by vacuum centrifugation
as previously described [35].
The pooled iTRAQ sample was resuspended in 50 ml of 25%
acetonitrile in 0.1% formic acid prior to loading through a home
made ziptip using 10 ml of 10% slurry of Poros HS in 50:50
methanol:water. The ziptip was then washed with 3625 ml of 25%
acetonitrile in 0.1% formic acid prior to loading of the pooled
iTRAQ sample. The ziptip was then washed with 3625 ml of 25%
acetonitrile in 0.1% formic acid prior to elution with a stepped
NaCl gradient in 25% acetonitrile in 0.1% formic acid. A fraction
of iTRAQ labelled peptides were then eluted with 2625 ml of 5–
800 mM NaCl (5, 10, 20, 50, 100,150, 200, 150, 300, 400, 800) in
25% acetonitrile in 0.1% formic acid. A final elution of the ziptip
with 200 mM NH4OH and 50% propanol was used to remove
the most hydrophobic peptides. Each fraction was then dried by
vacuum centrifugation and stored until mass spectrometry analysis
of pooled iTRAQ samples by nano liquid chromatography-mass
spectrometry/mass spectrometry (nLC-MS/MS). Prior to the
analysis, each dried SCX fraction was re-suspended in 35 ml of
1% formic acid and 10 ml aliquots were injected onto an Agilent
6520 Q-TOF using an Agilent 1200 series nanoLC system with
microfluidic interface as previously described [35].
Raw data files were converted to mascot generic file (mgf) by
MassHunter workstation software prior to merging of the files with
Mascot Daemon and subsequent database (IPI Mouse) searching
with the Mascot search engine (Matrix Science, Version 2.2). To
be considered as a protein with modified relative expression, the
peptide abundance (or average of all peptide abundances for
proteins identified by more than one unique peptide) had to be
modified by greater than 20% (up or down) [35]. For validation,
expression levels of a number of proteins which were identified by
a single peptide were quantified in freshly prepared tissue samples
using quantitative fluorescent western blotting (see above).
Ingenuity Pathways Analysis (IPA) statistical network analyses
were performed as previously described [18].
Drosophila degeneration screen
Drosophila orthologs of the designated mouse proteins were
identified, when available, using a reciprocal BLASTing approach
and the Ensembl website (ensemble.org). Available mutations were
identified in Flybase the following Drosophila mutant stocks were
obtained from the Bloomington Stock Center (Bloomington ID
#): 12900, 26277, 18382, 7762, 20497, 12301, 30075, 24665,
18046, 5595, 23173, 6671, 13491, 20672, 25213, 18502, 13446,
9109, 11876, 7084, 25107, 7938, 5708, 11734, 29228, 2247,
13491, 15889, 8479, 18884, 23097, 15642, 382, 32035, and 7617.
Mutant stocks on the X chromosome were crossed to OR22a-Gal4,
UAS-mCD8::GFP flies and males were used for the degeneration
screen. Stocks for mutants on the second chromosome were
crossed to Sp/Cyo; OR22a-Gal4, UAS-mCD8::GFP, and the progeny
were self-crossed to obtain homozygous mutant flies on the second
and OR22a-Gal4, UAS-mCD8::GFP on the third chromosome.
Similarly, stocks for mutants on the third chromosome were
crossed to OR22a-Gal4, UAS-mCD8::GFP; Dr/TM3 and the
progeny self-crossed to obtain homozygous mutant flies on the
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third chromosome and OR22a-Gal4, UAS-mCD8::GFP on the
second chromosome.
The Wallerian degeneration assay was performed as described
[21]. Briefly, flies were aged for 7 days after eclosion to allow
strong labeling of ORN axons with GFP. The left 3rd antennal
segment was then removed, and the flies aged for another 7 days.
The right antennal ORNs served as unlesioned controls. The fly
heads were then fixed in 4% formaldehyde/PBS/0.1% Tween,
and dissected. Fly brains were mounted in Vectashield and
examined by confocal microscopy where they were phenotypically
scored by an investigator who was unaware of the genotype. A
minimum of 10 animals were examined and assessed per mutant
strain.
Spontaneous degeneration in uninjured axons and synapses was
scored by eye using the following criteria: 0 = no evidence for
fragmentation of axons or loss of GFP fluorescence in the
glomerulus; 1 =,10% of axons showing fragmentation and/or
mild loss of GFP fluorescence in the glomerulus; 2 =,25% of
axons showing fragmentation and/or mild to moderate loss of
GFP fluorescence in the glomerulus; 3 =.50% of axons showing
fragmentation and/or moderate to severe loss of GFP fluorescence
in the glomerulus; 4 = only fragmented axons remaining and/or
severe loss of GFP fluorescence in the glomerulus; 5 = no GFP
signal remaining in axons or the glomerulus. Delayed degenera-
tion in injured axons and synapses was scored by eye using the
following criteria: 0 = no intact axons and no fragments remaining;
1 = no intact axons but fragmented debris remaining; 2 =,25% of
axons intact but with extensive fragmentation of surrounding
axons; 3 =,50% of axons intact with evidence for fragmentation
in surrounding axons; 4 =.75% of axons intact with only modest
amounts of fragmentation in surrounding axons; 5 = intact axons
and synapses with no evidence for fragmentation.
Statistical analysis
Statistical analyses were performed using either Ingenuity
Pathways Analysis (IPA) software (for analysis of proteomic data)
or GraphPad Prism software (for data from quantitative western
blots). P,0.05 was considered to be statistically significant.
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